CN116554263A - SIRT1 agonists and their use in the treatment of related diseases - Google Patents
SIRT1 agonists and their use in the treatment of related diseases Download PDFInfo
- Publication number
- CN116554263A CN116554263A CN202210106886.2A CN202210106886A CN116554263A CN 116554263 A CN116554263 A CN 116554263A CN 202210106886 A CN202210106886 A CN 202210106886A CN 116554263 A CN116554263 A CN 116554263A
- Authority
- CN
- China
- Prior art keywords
- sirt1
- compound
- amino acid
- arginine
- cysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010041191 Sirtuin 1 Proteins 0.000 title claims abstract description 123
- 239000000556 agonist Substances 0.000 title claims abstract description 29
- 201000010099 disease Diseases 0.000 title claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 14
- 102000000344 Sirtuin 1 Human genes 0.000 title claims abstract 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 102
- 208000009304 Acute Kidney Injury Diseases 0.000 claims abstract description 10
- 208000033626 Renal failure acute Diseases 0.000 claims abstract description 10
- 201000011040 acute kidney failure Diseases 0.000 claims abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 9
- 206010061218 Inflammation Diseases 0.000 claims abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 9
- 230000004054 inflammatory process Effects 0.000 claims abstract description 9
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 9
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 208000028389 Nerve injury Diseases 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- 230000008764 nerve damage Effects 0.000 claims abstract description 8
- 206010040047 Sepsis Diseases 0.000 claims abstract description 7
- 150000001413 amino acids Chemical class 0.000 claims description 60
- 229940024606 amino acid Drugs 0.000 claims description 59
- 235000001014 amino acid Nutrition 0.000 claims description 59
- 230000000694 effects Effects 0.000 claims description 59
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 32
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 31
- 235000009697 arginine Nutrition 0.000 claims description 26
- 239000004475 Arginine Substances 0.000 claims description 25
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 25
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 22
- 235000018417 cysteine Nutrition 0.000 claims description 21
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 20
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical class SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 19
- 239000004472 Lysine Chemical group 0.000 claims description 19
- 235000018977 lysine Nutrition 0.000 claims description 19
- 125000003636 chemical group Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical class C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 13
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 13
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical class OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 12
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical class C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical class CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical class OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical class CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 11
- 235000013922 glutamic acid Nutrition 0.000 claims description 11
- 239000004220 glutamic acid Chemical class 0.000 claims description 11
- 235000005772 leucine Nutrition 0.000 claims description 11
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical class OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical class C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 10
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical class OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical class OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical class OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical class CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 10
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical class CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 10
- 239000004473 Threonine Chemical class 0.000 claims description 10
- 235000004279 alanine Nutrition 0.000 claims description 10
- 235000003704 aspartic acid Nutrition 0.000 claims description 10
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical class OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Chemical class OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 10
- 235000014304 histidine Nutrition 0.000 claims description 10
- 235000006109 methionine Nutrition 0.000 claims description 10
- 229930182817 methionine Chemical class 0.000 claims description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical class OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 10
- 235000008729 phenylalanine Nutrition 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 235000008521 threonine Nutrition 0.000 claims description 10
- 235000002374 tyrosine Nutrition 0.000 claims description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical class OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 10
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical class OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical class OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical class NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical class CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical class OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical class OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 9
- 235000009582 asparagine Nutrition 0.000 claims description 9
- 229960001230 asparagine Drugs 0.000 claims description 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical class OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 9
- 235000004554 glutamine Nutrition 0.000 claims description 9
- 235000013930 proline Nutrition 0.000 claims description 9
- 235000004400 serine Nutrition 0.000 claims description 9
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical class CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical class CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical class CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- 235000014705 isoleucine Nutrition 0.000 claims description 7
- 235000018102 proteins Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 239000004474 valine Chemical class 0.000 claims description 7
- 235000014393 valine Nutrition 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical group [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 208000013223 septicemia Diseases 0.000 abstract description 3
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 116
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 24
- 238000006911 enzymatic reaction Methods 0.000 description 23
- 239000000758 substrate Substances 0.000 description 19
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 15
- 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 description 14
- 108091005770 SIRT3 Proteins 0.000 description 14
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 125000000539 amino acid group Chemical group 0.000 description 13
- 230000021736 acetylation Effects 0.000 description 12
- 238000006640 acetylation reaction Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 239000007795 chemical reaction product Substances 0.000 description 11
- 229960004679 doxorubicin Drugs 0.000 description 11
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 10
- -1 cyano, nitro, amino, hydroxy, carboxy Chemical group 0.000 description 10
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 9
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 9
- 102000011990 Sirtuin Human genes 0.000 description 9
- 108050002485 Sirtuin Proteins 0.000 description 9
- 235000021283 resveratrol Nutrition 0.000 description 9
- 229940016667 resveratrol Drugs 0.000 description 9
- BMLMGCPTLHPWPY-REOHCLBHSA-N (4R)-2-oxo-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSC(=O)N1 BMLMGCPTLHPWPY-REOHCLBHSA-N 0.000 description 8
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical class OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 8
- 102100022913 NAD-dependent protein deacetylase sirtuin-2 Human genes 0.000 description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 8
- 108010041216 Sirtuin 2 Proteins 0.000 description 8
- 238000003381 deacetylation reaction Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- BFNOPXRXIQJDHO-YDKGJHSESA-N 2''-O-acetyl-ADP-D-ribose Chemical compound O[C@H]1[C@@H](OC(=O)C)C(O)O[C@@H]1COP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC=NC(N)=C3N=C2)O1 BFNOPXRXIQJDHO-YDKGJHSESA-N 0.000 description 7
- 101000616738 Homo sapiens NAD-dependent protein deacetylase sirtuin-6 Proteins 0.000 description 7
- 101000616727 Homo sapiens NAD-dependent protein deacylase sirtuin-5, mitochondrial Proteins 0.000 description 7
- 102100021840 NAD-dependent protein deacetylase sirtuin-6 Human genes 0.000 description 7
- 102100021839 NAD-dependent protein deacylase sirtuin-5, mitochondrial Human genes 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 230000006196 deacetylation Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- SRNWOUGRCWSEMX-UHFFFAOYSA-N Adenosine diphosphate ribose Natural products C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OCC1OC(O)C(O)C1O SRNWOUGRCWSEMX-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IZJLAQMWJHCHTN-BPUTZDHNSA-N Cys-Trp-Arg Chemical compound N[C@@H](CS)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O IZJLAQMWJHCHTN-BPUTZDHNSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000001917 fluorescence detection Methods 0.000 description 4
- 238000003197 gene knockdown Methods 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 239000000816 peptidomimetic Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 125000001984 thiazolidinyl group Chemical group 0.000 description 4
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 125000003396 thiol group Chemical class [H]S* 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000017946 PGC-1 Human genes 0.000 description 2
- 108700038399 PGC-1 Proteins 0.000 description 2
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 2
- 102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003875 Wang resin Substances 0.000 description 2
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- LUKBXSAWLPMMSZ-UHFFFAOYSA-N resveratrol Chemical compound C1=CC(O)=CC=C1C=CC1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-UHFFFAOYSA-N 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FBVVGPMIPAZFAW-RZVRUWJTSA-N (2S)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H]1CCCN1 FBVVGPMIPAZFAW-RZVRUWJTSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YOJXPNNNKZABFE-BXRBKJIMSA-N (2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.OC[C@H](N)C(O)=O YOJXPNNNKZABFE-BXRBKJIMSA-N 0.000 description 1
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 description 1
- 125000006823 (C1-C6) acyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LAMQVIQMVKWXOC-UHFFFAOYSA-N 4-methyl-n-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(=O)NC1=CC=CC=C1C(N=C1SC=2)=CN1C=2CN1CCOCC1 LAMQVIQMVKWXOC-UHFFFAOYSA-N 0.000 description 1
- 102100025908 5-oxoprolinase Human genes 0.000 description 1
- 108090000900 5-oxoprolinase (ATP-hydrolyzing) Proteins 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101000859568 Methanobrevibacter smithii (strain ATCC 35061 / DSM 861 / OCM 144 / PS) Carbamoyl-phosphate synthase Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000001507 asparagine derivatives Chemical class 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000007037 hydroformylation reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108010005636 polypeptide C Proteins 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000021738 protein deacetylation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- IASPBORHOMBZMY-UHFFFAOYSA-N srt1720 Chemical compound C=1N=C2C=CC=CC2=NC=1C(=O)NC1=CC=CC=C1C(N=C1SC=2)=CN1C=2CN1CCNCC1 IASPBORHOMBZMY-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a compound which has a structure shown as a formula I, wherein the definitions of X0, X1, X2 and X3 are described in the specification and the claims. The compound provided by the invention, which is used as an SIRT1 agonist, has high subtype selectivity on SIRT1, and can be used for treating related diseases such as inflammation, covid-19, septicemia, diabetes, cancer, cardiovascular diseases, acute kidney injury, nerve injury, neurodegenerative diseases and the like. X0-X1-X2-X3 (I).
Description
Technical Field
The invention relates to the field of biological medicine, in particular to an SIRT1 agonist and application thereof in the treatment of related diseases.
Background
Sirtuins deacetylase is expressed as Nicotinamide Adenine Dinucleotide (NAD) + ) Catalytic protein deacetylation as cofactor with simultaneous NAD addition + To Nicotinamide (NAM) and 2' -O-acyl-ADP-ribose (OAADPr). Sirtuins have been found in humans in seven subtypes (SIRT 1-SIRT 7) which have distinct subcellular localization and functions, with SIRT1 being distributed in brain, heart, kidney, liver, retina, uterus, skeletal muscle, blood vessels, and adipose, etc., located primarily in the nucleus, and also transported through the nucleus to the cytoplasm, playing an important role in physiological processes, mainly in several ways: 1) SIRT1 affects chromatin condensation by deacetylating histones, regulating expression and activity of histones and their modifying enzymes, regulating transcription and expression of genes; 2) SIRT1 participates in DNA damage repair and body aging processes by regulating the acetylation levels of FOXO3a, LKB1 and p 53; 3) SIRT1 is very important for embryo and brain development, and only 20% of mouse fertilized eggs with SIRT1 gene deletion can develop and mature, but the development is slow, eyes and hearts are malformed, and brain infants appear or not; in addition, SIRT1 also has protective effects on neurons in traumatic brain injury and Alzheimer's disease; 4) The SIRT1 tissue specificity high expression in the myocardial cells can reduce the range affected by myocardial infarction and promote the recovery of the organism; 5) PGC-1 alpha inhibits the expression of glycolytic genes and the activities of glucokinase G6P and pyruvate kinase PEPCK, SIRT1 forms a compound with HNF4 alpha through deacetylation of PGC-1 alpha so as to regulate the expression of gluconeogenesis related genes and the activities of PEPCK and G6P and promote hepatic glucose metabolism; 6) Upregulation of SIRT1 promotes FOXO3a deacetylation, thereby inhibiting PUMA and alleviating Acute Kidney Injury (AKI); 7) SIRT1 is demonstrated by increasing lysosomal numbers and depletionAcetylation of lysosomal related proteins promotes degradation of beta-amyloid peptide (aβ) in primary astrocytes, which is beneficial for alleviating symptoms of Alzheimer's Disease (AD). Furthermore, in Huntington's Disease (HD) mouse models, specific knockouts of SIRT1 may lead to worsening brain pathology, while overexpression of SIRT1 may increase survival. It follows that the pleiotropic nature of SIRT1 makes it a hotspot target of interest in alleviating symptoms of aging, preventing and treating diseases associated with aging (such as inflammation, cardiovascular disease, neurodegenerative disease, diabetes and cancer). Therefore, a strong and high-selectivity SIRT1 agonist is developed to promote SIRT1 deacetylase reaction, and the SIRT1 agonist can be applied to the treatment of related diseases.
Several SIRT1 agonists have been reported to date, one of which is the natural product resveratrol, and there has been controversy in the past as to whether resveratrol is a true SIRT1 activator, because resveratrol shows activity that is actually caused by its interaction with a fluorescent group behind the substrate acetylated lysine, and if there is no fluorescent group or chemical group of a similar nature on the acetylated substrate, resveratrol has no effect on SIRT1 enzyme activity. In addition, some so-called SIRT1 agonists, such as SRT1720, that are synthesized artificially, can increase insulin sensitivity, decrease blood glucose levels, increase mitochondrial capacity in diet-induced obese or genetically mutated (Lepob/ob) mice, but in vivo it does not act directly on SIRT1 but via other signaling pathways; compound SRT2104, which has the same chemical backbone, exhibits poor pharmacokinetic properties when administered orally. In addition, 1, 4-dihydropyridine derivatives, 15-oxazolo [4,5-b ] pyridine and related heterocyclic analogs have also been reported as SIRT1 agonists. The activity exhibited by these compounds on SIRT1 depends on the fluorescent group behind the acetylated lysine, and only when the substrate's acetylated lysine residue is followed by a coumarin (AMC), rhodamine (TAMRA) fluorescent group or other similar chemical group, the promotion of SIRT1 enzyme activity by these compounds is observed in enzymatic experiments and therefore these compounds are now considered to be not real SIRT1 agonists. Even though these compounds are capable of promoting deacetylation of SIRT1 physiological substrates in a cellular or animal model, they are caused by other signaling pathways and do not act on SIRT1. Some of these compounds have entered phase I clinic on behalf of SIRT1 agonists, suggesting that SIRT1 agonists do have clinical application prospects, as well as the importance and urgency of developing true SIRT1 agonists.
Disclosure of Invention
The invention aims to provide an SIRT1 agonist which can promote SIRT1 enzyme activity.
In a first aspect of the present invention, there is provided a compound represented by the general formula (I),
X0-X1-X2-X3 (I)
wherein X0 is cysteine or a cysteine precursor procysteine;
x1 is any amino acid or amino acid analog;
x2 is arginine or lysine;
x3 is absent or is any chemical group, amino acid analog or amino acid analog modified with a chemical group at the carboxy terminus.
In another preferred embodiment, the chemical group is selected from the group consisting of: amidation, glycosylation, alcoholization, hydroformylation, ketonization, epoxyketonization, hydroxamate peptide, esterfication, N-alkylation, mercaptoethylamination, AMC, AFC, pNA, PEG, dap (Dnp), lys (Dye), rh110.
In another preferred embodiment, X1 is selected from: glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or an amino acid analog of the above type having a protecting group in the side chain or a non-protein derived amino acid analog thereof.
In another preferred embodiment, X3 is selected from: glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or an amino acid analog of the above type having a protecting group in the side chain or a non-protein derived amino acid analog thereof.
In another preferred embodiment, the amino acid analog is selected from the group consisting of: beta-amino acids, alpha-disubstituted amino acids, non-alpha-amino acids, secondary amine type amino acids, alpha, beta-double amino acids, sulfur containing amino acids, halogen containing amino acids, freidinger type amino acids.
In another preferred embodiment, the substituents in the α, α -disubstituted amino acids are each independently halogen, cyano, nitro, amino, hydroxy, carboxy, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 unsaturated hydrocarbyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C1-C6 acyl, substituted or unsubstituted C3-C12 cycloalkyl, -L1- (CH) 2 ) m-substituted or unsubstituted C6-C12 aryl, -L1- (CH) 2 ) m-substituted or unsubstituted 3-12 membered heterocyclyl, -L1- (CH) 2 )m-C(=O)-N(R 8 )(R 9 ) Wherein L1 is none, -O-, or-S-; m is 0, 1, 2, 3, 4 or 5; r is R 8 And R is 9 Each independently selected from: hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-12 membered heterocyclyl, or substituted or unsubstituted C6-C12 aryl;
each of the above substitutions is meant to comprise one or more substituents selected from the group consisting of: halogen, hydroxy, phenyl, C1-C12 alkyl, C1-C12 haloalkyl, C2-C12 unsaturated hydrocarbon, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C12 cyclic hydrocarbon, 3-12 membered heterocyclic, cyano, nitro, hydroxymethyl, carboxyl, mercapto.
In another preferred embodiment, X0, X1, X2, X3 are each independently L-form, D-form or DL-form.
In another preferred embodiment, X0 is cysteine, X1 is tryptophan, X2 is arginine, and X0, X1, X2 are not L-forms at the same time when X3 is absent.
In another preferred embodiment, X0 is cysteine;
x1 is tryptophan, aspartic acid, arginine, lysine, glutamine, glutamic acid, leucine, glycine, cysteine, proline, serine, threonine, histidine, alanine, methionine, tyrosine, or phenylalanine;
x2 is arginine or asparagine;
x3 is arginine, glutamic acid or tryptophan.
In a second aspect of the invention there is provided a pharmaceutical composition comprising a compound of the first aspect and a pharmaceutically acceptable carrier.
The novel compounds provided by the invention can be used singly or mixed with pharmaceutically acceptable auxiliary materials (such as excipient, diluent and the like) to prepare tablets, capsules, granules, syrups and the like for oral administration. The pharmaceutical composition can be prepared according to a conventional pharmaceutical method.
In another preferred embodiment, the pharmaceutical composition further comprises at least one additional therapeutic agent. Preferably, the at least one other therapeutic agent comprised in the pharmaceutical composition is selected from the group consisting of other anticancer agents, immunomodulators, anti-inflammatory agents, hypoglycemic agents, antiallergic agents, antiemetic agents, pain relieving agents, cytoprotective agents and combinations thereof.
In a third aspect of the invention there is provided the use of a compound according to the first aspect or a pharmaceutical composition according to the second aspect, (a) for the preparation of a SIRT1 agonist; or (b) for preparing a medicament for treating a disease associated with SIRT1 enzyme activity.
In another preferred embodiment, the disease associated with SIRT1 enzyme activity is selected from the group consisting of: inflammation, covid-19, sepsis, diabetes, cancer, cardiovascular disease, acute kidney injury, nerve injury, and neurodegenerative disease.
In a fourth aspect of the invention there is provided a method of non-therapeutically agonizing a SIRT1 enzyme in vitro comprising adding to a system in need thereof a compound as described in the first aspect or a pharmaceutical composition as described in the second aspect.
The present application provides chemical structures containing the amino acid sequence of X0-X1-X2-X3 (e.g., (Cys/procysteine) -X1- (Arg/Lys) -X3) and peptidomimetics thereof or compounds comprising these amino acid sequence formulae or peptidomimetics thereof, wherein X1 is any amino acid or amino acid analogue,x3 is not present or is any chemical group, amino acid analogue or amino acid analogue with modified chemical group at the carboxyl end, and the amino acid residue in the sequence can be L-type amino acid or D-type amino acid; the patent does not cover all L-type amino acids Cys-Trp-Arg polypeptides (the N-terminal and C-terminal of which are not chemically modified), but covers a peptide mimetic of Cys-Trp-Arg or a compound comprising such an amino acid sequence or peptide mimetic thereof, wherein the amino acid residues may be L-type amino acids or D-type amino acids. The compounds of the present application act as SIRT1 agonists, unlike the so-called "SIRT1 agonists" reported previously, whose promoting effect on SIRT1 enzymatic activity is independent of the chemical groups following the acetylation of lysine on the substrate, are true SIRT1 agonists, the-NH of Cys amino acid residues 2 and-SH on the side chain promotes dissociation of the reaction product from the enzyme complex by forming reversible covalent bonding with the C1' atom on the OAADPr sugar ring of the SIRT1 enzyme reaction product, thereby promoting SIRT1 enzyme reaction. The compound has high subtype selectivity to SIRT1 and can be used for treating related diseases such as inflammation, covid-19, septicemia, diabetes, cancer, cardiovascular diseases, acute kidney injury, nerve injury, neurodegenerative diseases and the like.
It is understood that within the scope of the present invention, the above-described technical features of the present invention and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. Each feature disclosed in the description may be replaced by alternative features serving the same, equivalent or similar purpose. And are limited to a space, and are not described in detail herein.
Drawings
In FIG. 1A) shows the principle of a fluorescence experiment for detecting SIRT1 to catalyze the deacetylation reaction of AMC labeled acetyl peptide. Trypsin is Trypsin; b) To determine the dose-response curves of the compounds of the present application and resveratrol (resveratrol) to promote SIRT1 enzymatic reactions using the AMC fluorescence detection method. The relative activities are shown in the figure, the initial enzyme activity (i.e.without compound) is set to 1, and when the value reaches 1.5, the EC is the compound 1.5 。
FIG. 2A) shows detection of SIRT1 catalyzed Abz markersThe principle of fluorescence experiments of the deacetylation reaction of the acetyl peptide is recorded. Trypsin is Trypsin; b) To determine the dose-response curve of the compounds of the present application and resveratrol (resveratrol) to promote SIRT1 enzymatic reaction using the Abz fluorescence detection method; c) As a result of HPLC analysis, the compound CERW is shown to promote SIRT1 to GQSTSRHKK ac Deacetylation of LM polypeptides.
FIG. 3A) is a dose-response curve of compound CWR to SIRT1, SIRT2, SIRT3, SIRT5, SIRT6 enzyme responses determined by AMC fluorescence assay; b) Determination of CWR versus SIRT3, SIRT3 for AMC fluorescence detection methods R158M Dose-effect histogram of enzyme response.
The mechanism by which compounds promote SIRT1 enzymatic reactions is shown in a) in fig. 4: the N-terminal alpha-amino nitrogen and side chain sulfhydryl of Cys amino acid residue of the compound form reversible covalent bonding with C1' atom on the OAADPr sugar ring of SIRT1 enzyme reaction product to promote dissociation of the reaction product from the enzyme complex, thereby promoting SIRT1 enzyme reaction; b) The dose-response curve of CWR and its N-terminal acetylated analogs to SIRT1 enzyme response was determined for the AMC fluorescence detection method. Wherein Ac-CWR is N-terminal acetylated CWR.
In fig. 5 a) shows the interaction of compound CWR with SIRT1, red representing the acetylated peptide; green, blue, yellow and red represent C, N, S, O atoms, respectively. The N-terminal alpha-amino nitrogen of cysteine residue, side chain sulfhydryl and OAADPr form thiazolidine ring, arginine in the compound is surrounded by Glu214, asp292 and Asp298 of SIRT1, and salt bridge (or electrostatic) interaction is formed. Dashed box inside: the distance between the conserved arginine Arg274 of SIRT1 and the carbon atom of the ADPr ribocyclic C1'; B-E) shows the distances between the conserved arginine corresponding to SIRT2, SIRT3, SIRT5, SIRT6 and the ADPr ribocyclic C1' carbon atom in sequence.
FIG. 6 shows that compounds affect intracellular p53 acetylation levels by acting on SIRT1, wherein A-B) control groups were treated with 5%o (v/v) DMSO, experimental groups were treated with 10. Mu.M DOX with 0. Mu.M, 5. Mu.M, 10. Mu.M, and 25. Mu.M compounds, where 0. Mu.M indicates the addition of equal volumes of water; c) After SIRT1 knockdown, compound C D W D R D Effects on intracellular p53 acetylation levels. The DOX group was treated with 10. Mu.M DOX,while the control group was treated with 5%o (v/v) DMSO, the experimental group was treated with 10. Mu.M DOX, 25. Mu. M C D W D R D And si-SIRT1 treatment at different concentrations (increasing concentrations from left to right). Error bars represent mean ± SEM (n=5) p compared to control group<0.05,***p<0.001. Single-factor analysis of variance for Newman-Keuls post-hoc test.
Detailed Description
The inventor of the application researches and researches extensively and intensively develop a compound with a general structure of X0-X1-X2-X3 (such as Cys-X1- (Arg/Lys) and Cys-X1- (Arg/Lys) -X3 amino acid sequence), which adopts a brand new action mechanism to promote SIRT1 enzyme activity: i.e. -NH of Cys amino acid residues 2 and-SH on the side chain promotes dissociation of the reaction product from the enzyme complex by forming reversible covalent bonding with the C1' atom on the OAADPr sugar ring of the SIRT1 enzyme reaction product, thereby promoting SIRT1 enzyme reaction. Unlike the so-called "SIRT1 agonists" reported previously, the promotion of SIRT1 enzyme activity by the compounds of the present application, independent of the chemical groups following the acetylation of lysine on the substrate, is a true SIRT1 agonist, and the change of residues from L-type amino acids to D-type amino acids does not lead to the loss of compound activity, which is beneficial for improving its metabolic stability. In addition, the compounds have high subtype selectivity to SIRT1, and have no influence on SIRT2, SIRT3, SIRT5 and SIRT6 enzyme activities. The compound of the present application, as an SIRT1 agonist, can be used for the treatment of inflammation, covid-19, sepsis, diabetes, cancer, cardiovascular disease, acute kidney injury, nerve injury, neurodegenerative disease and other related diseases. On this basis, the present invention has been completed.
Compounds of formula (I)
The compound has a structure shown in the following general formula:
X0-X1-X2-X3(I)
wherein X0 is procysteine or Cys;
since procysteine (CA: 19771-63-2; designation L-2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID) can be converted in vivo by 5-Oxo-L-procline (5-Oxo-L-prolinase) into Cysteine, this application covers chemical structures containing the amino ACID sequence formula (Cys/procysteine) -X1- (Arg/Lys), (Cys/procysteine) -X1- (Arg/Lys) -X3 and peptidomimetics thereof, or compounds containing these amino ACID sequence formulae or peptidomimetics thereof.
X1 is any amino acid or amino acid analog; in another preferred embodiment, X1 is selected from: glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or an amino acid analog of the above type having a protecting group in the side chain or a non-protein derived amino acid analog thereof.
X2 is arginine or lysine.
X3 is absent or is any chemical group, amino acid analog or amino acid analog modified with a chemical group at the carboxy terminus. In another preferred embodiment, X3 is selected from: glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or an amino acid analog of the above type having a protecting group in the side chain or a non-protein derived amino acid analog thereof.
The amino acid residues in the sequence may be L-type amino acids, D-type amino acids. In another preferred embodiment, X0, X1, X2, X3 are each independently of the other L-or D-form.
The general formula I does not cover all L-type amino acid Cys-Trp-Arg polypeptide (the N-end and the C-end of the polypeptide are not chemically modified), but covers a peptide mimetic of Cys-Trp-Arg or a compound containing the amino acid sequence or the peptide mimetic, wherein the amino acid residue can be L-type amino acid or D-type amino acid.
The compound adopts a brand new action mechanism to promote the activity of SIRT1 enzyme: i.e. -NH of Cys amino acid residues 2 and-SH on the side chain promotes dissociation of the reaction product from the enzyme complex by forming reversible covalent bonds with C1 atoms on the OAADPr sugar ring of the SIRT1 enzyme reaction productAnd (3) performing SIRT1 enzyme reaction.
Unlike the so-called "SIRT1 agonists" reported previously, the promotion of SIRT1 enzyme activity by the compounds of the present application, independent of the chemical groups following the acetylation of lysine on the substrate, is a true SIRT1 agonist, and the change of residues from L-type amino acids to D-type amino acids does not lead to the loss of compound activity, which is beneficial for improving its metabolic stability.
In addition, the compounds have high subtype selectivity to SIRT1, and have no influence on SIRT2, SIRT3, SIRT5 and SIRT6 enzyme activities.
Research has reported that promoting SIRT1 has positive protective effect on inflammation, covid-19, diabetes, breast cancer, cardiovascular diseases, acute kidney injury, nerve injury caused by cerebral ischemia, and neurodegenerative diseases. The compound of the present application, as an SIRT1 agonist, can be used for the treatment of inflammation, covid-19, sepsis, diabetes, cancer, cardiovascular disease, acute kidney injury, nerve injury, neurodegenerative disease and other related diseases.
Pharmaceutical composition
The invention also provides a pharmaceutical composition comprising an active ingredient in a safe and effective amount, and a pharmaceutically acceptable carrier.
The "active ingredient" as used herein refers to the compound of formula I as described herein.
The active ingredient and the pharmaceutical composition can promote SIRT1 enzyme activity, have high subtype selectivity on SIRT1, have no influence on SIRT2, SIRT3, SIRT5 and SIRT6 enzyme activity, and can be used for treating related diseases such as inflammation, covid-19, septicemia, diabetes, cancer, cardiovascular diseases, acute kidney injury, nerve injury, neurodegenerative diseases and the like.
"safe and effective amount" means: the amount of active ingredient is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical compositions contain 1-2000mg of active ingredient per dose, more preferably 10-200mg of active ingredient per dose. Preferably, the "one dose" is a tablet.
"pharmaceutically acceptable salt thereofAcceptable carrier "refers to: one or more compatible solid or liquid filler or gel materials which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. "compatibility" as used herein means that the components of the composition are capable of blending with and between the active ingredients of the present invention without significantly reducing the efficacy of the active ingredients. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, and the like), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, and the like), polyols (e.g., propylene glycol, glycerol, mannitol, sorbitol, and the like), emulsifiers (e.g.) Wetting agents (such as sodium lauryl sulfate), coloring agents, flavoring agents, stabilizing agents, antioxidants, preservatives, pyrogen-free water and the like.
The mode of administration of the active ingredient or pharmaceutical composition of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular, or subcutaneous), and the like.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of these substances and the like. In addition to these inert diluents, the compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active ingredient, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these substances, and the like.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
The compounds of the present invention may be administered alone or in combination with other therapeutic agents (e.g., antineoplastic agents, anti-inflammatory agents, etc.).
When a pharmaceutical composition is used, a safe and effective amount of the compound of the present invention is applied to a mammal (e.g., a human) in need of treatment, wherein the dose at the time of administration is a pharmaceutically effective dose, and the daily dose is usually 1 to 2000mg, preferably 20 to 500mg, for a human having a body weight of 60 kg. Of course, the particular dosage should also take into account factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled practitioner.
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental procedures, which do not address the specific conditions in the examples below, are generally carried out under conventional conditions (e.g.those described in Sambrook et al, molecular cloning: A laboratory Manual (New York: cold Spring Harbor Laboratory Press, 1989)) or under conditions recommended by the manufacturer. Percentages and parts are weight percentages and parts unless otherwise indicated.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred methods and materials described herein are presented for illustrative purposes only.
Amino acids and abbreviations are shown in the following table.
Name of the name | English | Three letters | Single letter |
Glycine (Gly) | Glycine | Gly | G |
Alanine (Ala) | Alanine | Ala | A |
Valine (valine) | Valine | Val | V |
Leucine (leucine) | Leucine | Leu | L |
Isoleucine (Ile) | Isoleucine | Ile | I |
Proline (proline) | Proline | Pro | P |
Phenylalanine (Phe) | Phenylalanine | Phe | F |
Tyrosine | Tyrosine | Tyr | Y |
Tryptophan | Tryptophan | Trp | W |
Serine (serine) | Serine | Ser | S |
Threonine (Thr) | Threonine | Thr | T |
Cysteine (cysteine) | Cystine | Cys | C |
Methionine | Methionine | Met | M |
Asparagine derivatives | Asparagine | Asn | N |
Glutamine | Glutarnine | Gln | Q |
Aspartic acid | Aspartic acid | Asp | D |
Glutamic acid | Glutamic acid | Glu | E |
Lysine | Lysine | Lys | K |
Arginine (Arg) | Arginine | Arg | R |
Histidine | Histidine | His | H |
Preparation of polypeptide Compounds
All polypeptides of the invention were synthesized using Wang resin, fmoc-based solid phase method, and the amino acid residues were coupled in sequence from the carboxy-terminus to the amino-terminus (i.e., right to left). Fmoc deprotection and coupling of amino acids are as follows: treating Wang resin with Fmoc-protected polypeptide rightmost amino acid residue with 20% piperidine to remove Fmoc protection; the second amino acid residue at the right end of the Fmoc-protected polypeptide was activated by 2- (1H-benzotriazole-1-oxy) -1, 3-tetramethyluronium Hexafluorophosphate (HBTU) in the presence of N-methylmorpholine (NMM) and reacted with the resin for 1 hour to couple with the Fmoc-deprotected amino acid on the resin. Repeating the Fmoc deprotection and coupling steps until all amino acid residues of the polypeptide are coupled to the resin, finally removing Fmoc on the polypeptide by trifluoroacetic acid (TFA) and cutting the Fmoc from the resin, and purifying the sample by High Performance Liquid Chromatography (HPLC) by using a C18 Pep RPC reverse phase column to obtain the pure target polypeptide (solvent A:0.1% TFA/water, solvent B:0.1% TFA/MeCN, flow rate: 10.0 ml/min, elution gradient: 10% -90% solvent B,30 min).
Example 1
Compounds containing Cys-X- (Arg/Lys) and Cys-X- (Arg/Lys) -X amino acid sequence general structure promote SIRT1 enzyme reaction
The literature experiments for screening SIRT1 agonists generally used a "Fluor de Lys" (FdL) peptide RHKKAc AMC as substrate (FIG. 1A). RHKK is derived from amino acid residues 379-382 of the SIRT1 physiological substrate p53 protein, wherein lysine 382 is acetylated, and 7-amino-4-methylcoumarin (AMC) is connected at the C-terminal, thus forming the so-called FdL. However, a disadvantage of this assay is that the compound interacts with the fluorophore AMC, resulting in a false positive result that the compound promotes SIRT1 enzyme activity. Thus, when using the "SIRT1 agonist" found using the FdL assay, agonist activity may not be observed in vivo because the natural state of the acetyllysine of the SIRT1 physiological substrate is not followed by a fluorescent or similar chemical moiety.
By usingFdL method (A in FIG. 1), 0.5. Mu.M SIRT1, 750. Mu.M NAD + Compounds of 31.25. Mu.M RHKKAcAMC and different concentrations (0.5. Mu.M, 1.5. Mu.M, 4.5. Mu.M, 13.5. Mu.M, 40.5. Mu.M, 121.5. Mu.M) were placed in enzyme reaction buffers (i.e.25 mM Tris-HCl, pH 8.0, 137mM NaCl, 2.7mM KCl, 1mM MgCl2) and reacted at 37℃for 45 minutes. Then, trypsin (0.5 mg/ml) containing 10mM nicotinamide was added and incubated at 37℃for 30min. The effect of the polypeptide compound CWR on SIRT1 enzyme activity was evaluated by measuring fluorescence at 340nm excitation wavelength and 490nm emission wavelength using a microplate reader (POLARstar OPTIMA, BMG Labtech) 1.5 At 3.16. Mu.M (B in FIG. 1), resveratrol (EC) was superior to the control compound 1.5 19.2 μm). Interestingly, peptide C containing amino acid form D D W D R D Is equivalent to CWR in activity, and the reverse D-form peptide R D W D C D Does not exhibit any activity. This suggests that the amino acid sequence of the compound is critical for activity, even a simple inversion of the amino acid sequence will result in a loss of activity.
To further verify the effect of amino acid chirality on activity, cysteines (Cys, C), tryptophan (Trp, W) and arginines (Arg, R) with different chiralities were combined without altering the amino acid sequence (including C D WR、CW D R、CWR D 、C D W D R、C D WR D 、CW D R D Wherein subscript D represents a D-form amino acid, and an L-form amino acid is not subscripted), and their activities are measured, it was found that the amino acid residue was changed from L-form to D-form without causing the loss of CWR activity (Table 1). These results indicate that the activity of compound CWR is largely dependent on amino acid sequence rather than amino acid chirality.
Agonistic activity of the compounds of Table 1 on SIRT1
a EC 1.5 : concentration of compound required to increase enzyme Activity by 50%
b Max A: maximum activation fold;
c NA: "non active", no activity
Example 2
The activity of the compound is independent of the fluorescent group AMC on the acetylated substrate
To exclude that the activating effect of compound CWR is due to the interaction of compound and AMC, compound activity was further verified using other assays and substrates.
Use of the acetylated polypeptide Abz-GVLKacAY NO2 GV-NH 2 As substrate, the peptide is derived from carbamoyl phosphate synthetase 1 (CPS 1) (a in fig. 2). 0.05. Mu.M SIRT1, 500. Mu.M NAD + 、10μMAbz-GVLKacAY NO2 After reaction of GV-NH2 and compounds of different concentrations (0.5. Mu.M, 1.5. Mu.M, 4.5. Mu.M, 13.5. Mu.M, 40.5. Mu.M, 121.5. Mu.M) at 37℃for 30 minutes, trypsin (0.01 mg/ml) containing 10mM nicotinamide was added, incubation at 37℃for 15 minutes, and fluorescence of the enzyme reaction product Abz-GCLK was measured at 320nm excitation wavelength, 420nm emission wavelength (A in FIG. 2) and the effect of the compounds on SIRT1 enzyme activity was evaluated.
Experimental results show that CWR and C D W D R D Is still present, and R D W D C D Remain inactive (B in fig. 2). In contrast, no activity of the control compound resveratrol was observed, which further confirms: unlike resveratrol, the promoting effect of compounds containing Cys-X1- (Arg/Lys) and Cys-X1- (Arg/Lys) -X3 amino acid sequence general structure on SIRT1 enzyme activity is irrelevant to the fluorescent group AMC.
Due to the acetylated polypeptide Abz-GVLKacAY NO2 GV-NH 2 The fluorescent group Abz is still arranged at the amino end, and in order to examine the influence of the compound on SIRT1 enzyme reaction under the condition that an acetylated substrate is in an unmodified state, the activity of the compound is evaluated by quantitatively analyzing the amount of SIRT1 enzyme reaction products by adopting a High Performance Liquid Chromatography (HPLC) method. Fluorescent-free acetylated substrates (GQSTRHKKAcLM) and deacetylated substrates(GQSTSRHKKLM) retention times on HPLC were 6.8 min and 6.0min, respectively. In preliminary experiments, the retention times of compound CWR and deacetylated substrate GQSTSRHKKLM were found to be very close and difficult to distinguish, which prevented quantitative analysis of the enzyme reaction product GQSTSRHKKLM in the presence of compound CWR, and therefore, another compound, CERW, was designed to be synthesized with a retention time that was significantly different from that of GQSTSRHKKLM, and showed similar activity to CWR as measured by FdL method (fig. 1 a) (table 1). The results of the HPLC experiments are shown in FIG. 2C, and the peak area at 6.0min of the retention time is significantly greater for the experimental group with compound CERW than for the control group without CERW, indicating that compound CERW promotes SIRT1 enzyme reaction, and that under the same reaction conditions, the experimental group produced a greater amount of deacetylated peptide GQSTSRHKKLM than the control group, which clearly demonstrated that the activity of the compound was independent of the fluorescent group behind the acetylated lysine residue of the substrate.
Example 3
Mechanism of promoting SIRT1 enzyme reaction by compounds and reason for SIRT1 selective action
Each sirtuins has its unique role in the physiological process, and therefore the development of SIRT1 agonists should take into account their selectivity.
The activity of compound CWR on SIRT2/3/5/6 (SIRT 2, SIRT3, SIRT5, SIRT6 concentrations of 0.62. Mu.M, 1.0. Mu.M, 1.2. Mu.M, 5.0. Mu.M, respectively) was determined using the assay method described in example 1 and was found to have no effect on these enzymes (FIG. 3A). Based on the structure-activity relationship of the compounds, it was deduced that the high selectivity of compound CWR for SIRT1 should originate from the fact that the cysteine of the compound covalently binds to SIRT1 amino acid residues in the vicinity of SIRT1 enzyme reaction product oadpr (fig. 4 a), and therefore, based on the N-terminal α -amino nitrogen of the cysteine residue of compound CWR, the side chain thiol and oadpr, a thiazolidine ring is formed and CWR is docked into SIRT1 using a molecular modeling method (fig. 5 a). Arginine in CWR was found to be surrounded by acidic amino acids of Glu214, asp292 and Asp298 and to form a salt bridge (or electrostatic) interaction with these residues, thus the side chain of the amino acid residue at the third position of the compound is positively charged (e.g., arg, lys) and the interaction of the compound with SIRT1 can be enhanced.
Based on the model of the binding of the compound to SIRT1, amino acid residues around the thiazolidine ring were found to be very conserved in SIRT 1/2/3/5/6. However, the distance between the C1' carbon atom of the ADPr (adenosine diphosphate ribose) ribose ring in SIRT1 and the conserved arginine (i.e., arg274 in SIRT 1) is significantly different from other sirtuins, as compared to SIRT 2/3/5/6. The distance between Arg274 of SIRT1 and C1' of ADPr ribose ring isWhile SIRT2 (PDB ID:5D 7O), SIRT3 (PDB ID:4BN 4), SIRT5 (PDB ID:4F 56), SIRT6 (PDB ID:3 PKI) correspond to arginine at a distance from C1', respectively And->(B-E in FIG. 5). It is speculated that in SIRT2/3/5/6, this conserved arginine residue competes with the alpha-amino nitrogen N-terminal to the cysteine residue of the compound, attacking the C1' carbon atom of the ribose ring in OAADPr, thereby preventing thiazolidine ring formation, which is why the compounds of the present application selectively promote SIRT1 enzymatic reactions.
To confirm this view, mutation of Arg158, a conserved arginine residue in SIRT3, to Met, interestingly mutant SIRT3 R158M The disappearance of the enzyme activity of (2) suggests that conserved Arg158 is critical for SIRT3 enzyme activity, consistent with the above presumption. When the compound CWR is added into the reaction system, the CWR restores the mutant SIRT3 R158M Enzyme activity and promote SIRT3 in a concentration dependent manner R158M Enzymatic reaction (B in FIG. 3). This suggests that the selectivity of the compounds of the present application for SIRT1 is indeed due to the difference in distance between this conserved arginine residue in SIRT1/2/3/5/6 and C1' of the OAADPr ribose ring.
Example 4
Compounds acting on SIRT1 promote intracellular p53 deacetylation
p53 is a physiological substrate for SIRT1 and modulation of SIRT1 enzymatic reactions alters the level of acetylation of p53. To verify the activity of the compounds of the present application at the cellular level, human breast cancer MCF-7 cells were placed at 37℃with 5% CO 2 Is grown in DMEM (Gibco, product No. 12430-054) medium containing 10% FBS (Gibco, product No. 10091-148). To examine the effect of compounds on p53 acetylation levels, MCF-7 cells were treated with various concentrations of compounds (5. Mu.M, 10. Mu.M, 25. Mu.M) and 10. Mu.M Doxorubicin (DOX) for 6 hours. As a control, MCF-7 cells without doxorubicin and compound were incubated for 6 hours. Then, the cells were washed three times with PBS, and the cells were collected for western blot analysis (p 53 antibody, abcam, product number: AB75754; p53 (K382 acetylated) antibody, abcam, product number: AB 754).
The experimental method is adopted, C is respectively adopted D W D R D The MCF-7 breast cancer cells were treated with SWR and Doxorubicin (DOX), which induced apoptosis of the MCF-7 cells to produce a large number of acetylated p53. The results show that following compound C D W D R D Increasing concentrations gradually decreased the level of p53 acetylation, while SWR did not affect the p53 acetylation level (a-B in fig. 6).
Next, it was tested by gene knock-down experiments whether compounds promote intracellular p53 deacetylation by acting on SIRT1. mu.L of opti medium containing 8. Mu.L of liposomal lipo 2000 was added to another 250. Mu.L of opti medium containing SIRT1 siRNA (12 nM,24nM,48nM,96 nM), mixed well and left to stand for 20 min, and then added to MCF-7 cells containing 4.5mL of DMEM medium at 37℃with 5% CO 2 Incubate in incubator for 4 hours. The medium was removed by centrifugation and replaced with 5mL of DMEM medium containing 10% FBS, and the culture was continued for 12 hours. The medium was removed again and replaced with 5mL serum free DMEM medium, 25 μ M C D W D R D And 10. Mu.M DOX was incubated with the cells for 6 hours. As a control, MCF-7 cells without doxorubicin, compound were incubated for 6 hours, while as DOX group, 10. Mu.M DOX was incubated with MCF-7 cells for 6 hours. These samples were collected for western blot analysis.
The knockdown experiment result shows that the SIRT1 expression level in the MCF-7 is gradually reduced along with the increase of the SIRT1-siRNA concentration (C in figure 6), which shows that the SIRT1 knockdown is successful. Furthermore, with increasing SIRT1-siRNA concentration (15 nM, 30nM, 60nM, 120 nM), the amount of acetylated p53 expression was gradually increased, which indicated that C D W D R D The effect of reducing p53 acetylation gradually decreases, and the compound reduces p53 acetylation level by selectively acting on intracellular SIRT1.
All documents mentioned in this application are incorporated by reference as if each were individually incorporated by reference. Further, it will be appreciated that various changes and modifications may be made by those skilled in the art after reading the above teachings, and such equivalents are intended to fall within the scope of the claims appended hereto.
Claims (10)
1. A compound of the general formula (I),
X0-X1-X2-X3 (I)
wherein X0 is cysteine or a cysteine precursor;
x1 is any amino acid or amino acid analog;
x2 is arginine or lysine;
x3 is absent or is any chemical group, amino acid analog or amino acid analog modified with a chemical group at the carboxy terminus.
2. The compound of claim 1, wherein X1 is selected from the group consisting of: glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or an amino acid analog of the above type having a protecting group in the side chain or a non-protein derived amino acid analog thereof.
3. The compound of claim 1, wherein X3 is selected from the group consisting of: glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or an amino acid analog of the above type having a protecting group in the side chain or a non-protein derived amino acid analog thereof.
4. The compound of claim 1, wherein X0, X1, X2, X3 are each independently L-form, D-form or DL-form.
5. The compound of claim 1, wherein X0 is cysteine, X1 is tryptophan, X2 is arginine, and X0, X1, X2 are not L-forms at the same time when X3 is absent.
6. The compound of claim 1, wherein X0 is cysteine;
x1 is tryptophan, aspartic acid, arginine, lysine, glutamine, glutamic acid, leucine, glycine, cysteine, proline, serine, threonine, histidine, alanine, methionine, tyrosine, or phenylalanine;
x2 is arginine or asparagine;
x3 is arginine, glutamic acid or tryptophan.
7. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
8. The use of a compound of claim 1 or a pharmaceutical composition of claim 7, (a) for the preparation of a SIRT1 agonist; or (b) for preparing a medicament for treating a disease associated with SIRT1 enzyme activity.
9. The use of claim 8, wherein the disease associated with SIRT1 enzyme activity is selected from the group consisting of: inflammation, covid-19, sepsis, diabetes, cancer, cardiovascular disease, acute kidney injury, nerve injury, and neurodegenerative disease.
10. A method of non-therapeutically agonizing a SIRT1 enzyme in vitro comprising adding a compound according to claim 1 to a system in need thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210106886.2A CN116554263A (en) | 2022-01-28 | 2022-01-28 | SIRT1 agonists and their use in the treatment of related diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210106886.2A CN116554263A (en) | 2022-01-28 | 2022-01-28 | SIRT1 agonists and their use in the treatment of related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116554263A true CN116554263A (en) | 2023-08-08 |
Family
ID=87495266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210106886.2A Pending CN116554263A (en) | 2022-01-28 | 2022-01-28 | SIRT1 agonists and their use in the treatment of related diseases |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116554263A (en) |
-
2022
- 2022-01-28 CN CN202210106886.2A patent/CN116554263A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI118325B (en) | Multicatalytic protease inhibitors | |
JP5176964B2 (en) | Dipeptidyl peptidase IV inhibitor | |
US6825317B2 (en) | Cyclic tetrapeptide derivatives and pharmaceutical uses thereof | |
US20220098260A1 (en) | BH4 Stabilized Peptides And Uses Thereof | |
JP2012236828A (en) | Composition and method for counteracting effect of reactive oxygen species and free radicals | |
US20080182797A1 (en) | Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species | |
CN106413757A (en) | P97-polynucleotide conjugates | |
CA3129636A1 (en) | Triamterene or nolatrexed for use in the treatment of phenylketonuria | |
Velayutham et al. | Antiproliferation of MP12 derived from a fungus, Aphanomyces invadans virulence factor, cysteine-rich trypsin inhibitor on human laryngeal epithelial cells, and in vivo zebrafish embryo model | |
Sudnitsyna et al. | Methylglyoxal and small heat shock proteins | |
US20060160748A1 (en) | Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof | |
CN116554263A (en) | SIRT1 agonists and their use in the treatment of related diseases | |
US20200009221A1 (en) | Methods for inhibiting necrosis | |
ES2819238T3 (en) | Protein X polypeptide pharmaceutical agent against hepatitis B virus | |
ES2387435B1 (en) | USE OF HEPTAPEPTIDES FOR HYPERTENSION CONTROL | |
KR102043992B1 (en) | Novel staple peptides for inhibiting NCOA1/STAT6 protein-protein interaction and uses thereof | |
EP4233917A1 (en) | Anti-infective conjugate for use in the treatment of zika virus infection | |
JP7505790B2 (en) | Compounds for use in the treatment of phenylketonuria - Patent Application 20070223333 | |
ES2952984T3 (en) | Anticancer peptides and their uses | |
JP7185874B2 (en) | Labyrinthopeptin as an antiviral agent | |
WO2023235109A1 (en) | Novel main protease inhibitors, and compositions and methods thereof | |
TW202334180A (en) | Method for optimizing viral membrane fusion inhibitors as well as broad-spectrum anti-coronavirus lipopeptides and the application thereof | |
JP2003176298A (en) | Anti-hiv agent | |
US20090298782A1 (en) | Compounds for Delivering Amino Acids or Peptides with Antioxidant Activity into Mitochondria and Use Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |